Which of the following is the most important nursing action to perform before initiating adalimumab therapy in a patient with Crohn's disease?

A. Assess for manifestations of infection: Adalimumab is a tumor necrosis factor (TNF) inhibitor that suppresses the immune system to reduce inflammation in Crohn’s disease. Immunosuppression increases susceptibility to infections, including latent tuberculosis and opportunistic pathogens. Prior to initiating therapy, assessing for signs of active infection and screening for latent TB is critical to prevent serious complications. B. Obtain a baseline blood sugar level: Monitoring blood glucose is important for patients on corticosteroids or other medications that affect glucose metabolism, but adalimumab does not directly impact blood sugar. Baseline glucose assessment is not a priority action before starting this biologic therapy. C. Evaluate the patient's appetite: Appetite assessment provides general nutritional information but does not influence the safe initiation of adalimumab. While overall nutritional status may affect disease management, it is not the most urgent pre-treatment consideration. D. Check blood urea nitrogen levels: BUN assessment evaluates renal function, which may be relevant for certain medications eliminated renally, but adalimumab is primarily metabolized via reticuloendothelial pathways. Baseline BUN is not essential before starting this immunosuppressive therapy.